A year marked by a dual movement \u2014 technical and human \u2014 that redefined the company\u2019s trajectory. Because bringing robotics to the heart of vitreoretinal surgery requires more than innovation: it requires building, structuring, aligning, and growing. And that is exactly what happened.<\/strong><\/p>\n\n\n\n On the international scientific stage, Luca\u00ae<\/sup> reached a new level of recognition.Presented at AAO in Orlando, Euretina in Paris and other local conferences, the robot drew the attention of leading vitreoretinal surgeons \u2014 a field where stability, finesse, and repeatability are measured in microns.<\/p>\n\n\n\n In 2025, several key opinion leaders traveled to Montpellier to test the platform firsthand:<\/p>\n\n\n\n These unanimous and enthusiastic responses confirmed \u2014 for the team and for the scientific community \u2014 that robotics has its place in retinal surgery<\/strong>, and that Luca<\/strong>\u00ae<\/sup><\/strong> is opening the way.<\/strong><\/p>\n\n\n\n Developing a robot designed for the human eye requires extreme precision.Bringing it to the operating room requires an even more precise organization.<\/p>\n\n\n\n In 2025, AcuSurgical took an important step in its natural evolution: from a fast-growing start-up into a company entering its next phase of maturity, moving closer to clinical delivery.<\/strong><\/p>\n\n\n\n The implementation of squads helped strengthen collaboration and clarity across teams. Each R&D team \u2014 System, Hardware, Software, Test \u2014 found its place within a dynamic that offered shared clarity on objectives, roles, and interactions.<\/p>\n\n\n\n As one Engineer put it: \u201cAs a squad, we don\u2019t discover decisions downstream \u2014 we build them together.\u201d<\/strong><\/p>\n\n\n\n These squads are the rope<\/em> connecting talents:the one that prevents slipping,that sets the pace,that helps the team move forward together despite steep technical challenges.<\/p>\n\n\n\n As a RA\/QA Manager notes: \u201cWe\u2019re speaking the same language.\u201d<\/strong><\/p>\n\n\n\n All teams from R&D, RA\/QA, Product and Clinical have continued to grow and structure their work, enabling the company to approach the next steps with a reinforced stability and alignment.<\/p>\n\n\n\n One of the most important moments of the year was the robot\u2019s design freeze<\/strong>.<\/p>\n\n\n\n After an intense year during which R&D tackled major technical challenges, the teams reached a long-awaited point: a moment marking the transition from development to consolidation.<\/p>\n\n\n\n This milestone strengthened the foundation for the next clinical steps \u2014 particularly the upcoming FIH-2 \u2014 by reinforcing system stability and enabling the preparation of the verification phase, following the successful completion of FIH-1 in 2024.<\/p>\n\n\n\n As summarized by C\u00e9cile Genevieve, R&D Director<\/strong>: <\/p>\n\n\n\n \u201cWe had to make choices, define trade-offs, structure requirements, integrate new talents, and adopt new methods \u2014 all within a tight schedule.\u201d<\/strong><\/p>\n<\/blockquote>\n\n\n\n This collective effort now enables AcuSurgical to approach 2026 with a more mature, more reliable robot \u2014 ready to enter the crucial verification phase, with FIH-2 planned for 2026<\/strong>.<\/p>\n\n\n\n If one had to summarize 2025, perhaps the best words would be those of Arnaud Tellier, VP Product Strategy<\/strong>: <\/p>\n\n\n\n \u201cA year where clinical expertise met technological innovation, in an atmosphere of genuine collaboration.\u201d<\/p>\n<\/blockquote>\n\n\n\n Smiles around a robot,<\/p>\n\n\n\n heated discussions during a test,<\/p>\n\n\n\n friendly evenings where the team reimagined the world (and sometimes the algorithm).<\/p>\n\n\n\n These are the moments \u2014 simple, authentic \u2014 that best illustrate AcuSurgical in 2025.<\/p>\n\n\n\n A culture built on collaboration, mutual support, humility\u2026 but also pride. The pride of advancing a project that matters. The pride of welcoming surgeons from around the world. The pride of seeing Luca\u00ae<\/sup> gain credibility. The pride of opening a new chapter in ophthalmic robotics.<\/p>\n\n\n\n Everything structured, built, and consolidated in 2025 now leads to major steps where LUCA must demonstrate robustness, repeatability, and adoption in multiple surgical environments.<\/p>\n\n\n\n Beyond that, one ambition remains intact:<\/p>\n\n\n\n![\"\"](\"https:\/\/acusurgical.vivir.pw\/wp-content\/uploads\/2026\/03\/7574e8_406b797e29414a4483b3899894c2bc52mv2.png\")
<\/figure>\n\n\n\nA Climb in Credibility for a Robot That Is Changing the Game<\/strong><\/h2>\n\n\n\n
\n
![\"\"](\"https:\/\/acusurgical.vivir.pw\/wp-content\/uploads\/2026\/03\/7574e8_c6bc62a4f39744708abbd10dab0ab54dmv2-1024x274.png\")
<\/figure>\n\n\n\nA New Internal Rhythm: Connecting, Clarifying, Synchronizing<\/strong><\/h2>\n\n\n\n
Technical Progress: Scaling a Decisive Wall<\/strong><\/h2>\n\n\n\n
\n
A Demanding Year, Fueled by Exceptional Energy<\/strong><\/h2>\n\n\n\n
\n
![\"\"](\"https:\/\/acusurgical.vivir.pw\/wp-content\/uploads\/2026\/03\/7574e8_3913b375e0174630b49dc5c93755fa00mv2.png\")
<\/figure>\n\n\n\nAfter 2025\u2026 Continuing the Ascent<\/strong><\/h2>\n\n\n\n
\n